a College of Natural Resources & Life Science/Life and Industry Convergence Research Institute , Pusan National University , Miryang , Korea.
b Life Science Research Institute, Novarex Co., Ltd , Chungju , Korea.
Pharm Biol. 2018 Dec;56(1):309-317. doi: 10.1080/13880209.2018.1474932.
Quercetin (QCT) has been known as a potential therapeutic strategy for gastrointestinal diseases because it contributes to the stabilization of mast cells, the prevention of histamine release and modulation of CaCC chloride channel.
We investigated the laxative effect and action mechanism of QCT in Lop-induced constipation model.
Constipation of SD rats was induced by subcutaneous injection of loperamide (Lop) (4 mg/kg weight) in 0.5% Tween 20 twice a day for three days. After 24 h, the constipation group was further treated with 1× PBS (Lop + Vehicle treated group), 10 mg/kg of QCT (Lop + LQCT treated group), 20 mg/kg of QCT (Lop + MQCT treated group) or 40 mg/kg QCT (Lop + HQCT treated group) at once. At 24 h after QCT treatment, the constipation phenotypes were measured and the transverse colon was collected from SD rats.
The gastrointestinal motility, the number of stools and histological structures were significantly recovered in Lop + QCT treated group compared with the Lop + Vehicle treated group. Also, above activity of epithelial cells and smooth muscle cells were regulated by the mRNA expression of the muscarinic acetylcholine receptors M2 and M3 (mAChR M2 and M3) and some mediators of their downstream signalling pathway. Finally, laxative effects of QCT on mAChR signalling pathway were significantly inhibited by the treatment of mAChR antagonist in primary smooth muscle of rat intestine cells (pRISMCs).
This study provides the first strong evidence that QCT can be considered an important candidate for improving chronic constipation induced by Lop treatment in animal models.
槲皮素(QCT)已被认为是治疗胃肠道疾病的一种潜在策略,因为它有助于稳定肥大细胞,防止组胺释放并调节 CaCC 氯离子通道。
我们研究了 QCT 在洛匹那韦诱导的便秘模型中的通便作用和作用机制。
通过每天两次皮下注射洛匹那韦(Lop)(4mg/kg 体重)在 0.5%吐温 20 中诱导 SD 大鼠便秘(Lop 诱导的便秘模型),持续三天。24 小时后,将便秘组进一步用 1×PBS(Lop+Vehicle 处理组)、10mg/kg QCT(Lop+LQCT 处理组)、20mg/kg QCT(Lop+MQCT 处理组)或 40mg/kg QCT(Lop+HQCT 处理组)一次性处理。在 QCT 处理后 24 小时,测量便秘表型并从 SD 大鼠中收集横结肠。
与 Lop+Vehicle 处理组相比,Lop+QCT 处理组的胃肠动力、粪便数量和组织学结构均得到显著恢复。此外,上皮细胞和平滑肌细胞的上述活性通过毒蕈碱乙酰胆碱受体 M2 和 M3(mAChR M2 和 M3)及其下游信号通路的一些介质的 mRNA 表达来调节。最后,通过在大鼠肠细胞原代平滑肌(pRISMCs)中用 mAChR 拮抗剂处理,QCT 对 mAChR 信号通路的通便作用明显受到抑制。
这项研究首次提供了强有力的证据,表明 QCT 可被视为改善洛匹那韦治疗动物模型中慢性便秘的重要候选药物。